Trial · NCT03134222
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period (Up to Week 12) | STARTED | Lanraplenib 30 mg | 19 | |
| Treatment Period (Up to Week 12) | STARTED | Filgotinib 200 mg | 18 | |
| Treatment Period (Up to Week 12) | STARTED | Placebo | 10 | |
| Treatment Period (Up to Week 12) | STARTED | Placebo to Lanraplenib 30 mg | 0 | |
| Treatment Period (Up to Week 12) | STARTED | Placebo to Filgotinib 200 mg | 0 | |
| Treatment Period (Up to Week 12) | COMPLETED | Lanraplenib 30 mg | 14 | |
| Treatment Period (Up to Week 12) | COMPLETED | Filgotinib 200 mg | 14 | |
| Treatment Period (Up to Week 12) | COMPLETED | Placebo | 8 | |
| Treatment Period (Up to Week 12) | COMPLETED | Placebo to Lanraplenib 30 mg | 0 | |
| Treatment Period (Up to Week 12) | COMPLETED | Placebo to Filgotinib 200 mg | 0 | |
| Treatment Period (Up to Week 12) | NOT COMPLETED | Lanraplenib 30 mg | 5 | |
| Treatment Period (Up to Week 12) | NOT COMPLETED | Filgotinib 200 mg | 4 | |
| Treatment Period (Up to Week 12) | NOT COMPLETED | Placebo | 2 | |
| Treatment Period (Up to Week 12) | NOT COMPLETED | Placebo to Lanraplenib 30 mg | 0 | |
| Treatment Period (Up to Week 12) | NOT COMPLETED | Placebo to Filgotinib 200 mg | 0 | |
| Treatment Period (Week 12 to 48) | STARTED | Lanraplenib 30 mg | 14 | |
| Treatment Period (Week 12 to 48) | STARTED | Filgotinib 200 mg | 14 | |
| Treatment Period (Week 12 to 48) | STARTED | Placebo | 0 | |
| Treatment Period (Week 12 to 48) | STARTED | Placebo to Lanraplenib 30 mg | 4 | |
| Treatment Period (Week 12 to 48) | STARTED | Placebo to Filgotinib 200 mg | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03134222/flow